Assembly of Benzothiazine and Triazole in a Single Molecular Entity: Synthesis of -Oxicam Derived Novel Molecules as Potential Antibacterial/ Anti-cancer Agents

Author(s): Papigani Neeraja, Suryapeta Srinivas, Venkanna Banothu, B. Sridhar, Khagga Mukkanti, Pramod Kumar Dubey, Sarbani Pal*

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 20 , Issue 10 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Benzothiazine derivatives, because of their various biological activities have attracted particular attention in Med Chem and drug discovery efforts. The synthetic modifications of 1,2-benzothiazine 1,1-dioxides have been undertaken in order to explore and identify novel compounds or new analogues possessing promising biological activities. In our effort we have designed -oxicam derived bezothiazine-1,2,3-triazole derivatives as potential antibacterial agents.

Methods: These compounds were synthesized via a multi-step sequence involving the Cu catalyzed azide- alkyne cycloaddition (CuAAC) as a key step. The CuAAC proceeded at room temperature in DMF to afford 26 novel molecules in good (70-90%) yields.

Results: All these compounds were tested for their antibacterial properties against four strains of bacterial microorganisms and subsequently cytotoxic properties against lung and colon cancer cell lines. The compound 4e showed activities against majority of the bacterial species used (nearly comparable to amoxicillin, ciprofloxacin and ofloxacin against P. vulgaris) whereas 4d and 4f showed cytotoxicities selective towards cancer cells.

Conclusion: The present bezothiazine-1,2,3-triazole framework represents a new template for the identification of novel and potent antibacterial/anticancer agents.

Keywords: Benzothiazine, 1, 2, 3-triazole, azide, antibacterial activity, cytotoxicity, anticancer agents.

[1]
Zia-ur-Rehman, M.; Choudary, J.A.; Elsegood, M.R.; Siddiqui, H.L.; Khan, K.M. A facile synthesis of novel biologically active 4- hydroxy-N'-(benzylidene)-2H-benzo[e][1,2]thiazine-3-carbohydrazide 1,1-dioxides. Eur. J. Med. Chem., 2009, 44(3), 1311-1316.
[http://dx.doi.org/10.1016/j.ejmech.2008.08.002] [PMID: 18804313]
[2]
Ahmad, M.; Siddiqui, H.L.; Zia-ur-Rehman, M.; Parvez, M. Anti-oxidant and anti-bacterial activities of novel N′-arylmethylidene-2-(3, 4-dimethyl-5, 5-dioxidopyrazolo[4,3-c][1,2]benzothiazin-2(4H)-yl) acetohydrazides. Eur. J. Med. Chem., 2010, 45(2), 698-704.
[http://dx.doi.org/10.1016/j.ejmech.2009.11.016] [PMID: 19962218]
[3]
Ahmad, N.; Zia-ur-Rehman, M.; Siddiqui, H.L.; Ullah, M.F.; Parvez, M. Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents. Eur. J. Med. Chem., 2011, 46(6), 2368-2377.
[http://dx.doi.org/10.1016/j.ejmech.2011.03.020] [PMID: 21470723]
[4]
Sabatini, S.; Gosetto, F.; Serritella, S.; Manfroni, G.; Tabarrini, O.; Iraci, N.; Brincat, J.P.; Carosati, E.; Villarini, M.; Kaatz, G.W.; Cecchetti, V. Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors. J. Med. Chem., 2012, 55(7), 3568-3572.
[http://dx.doi.org/10.1021/jm201446h] [PMID: 22432682]
[5]
Barreca, M.L.; Manfroni, G.; Leyssen, P.; Winquist, J.; Kaushik-Basu, N.; Paeshuyse, J.; Krishnan, R.; Iraci, N.; Sabatini, S.; Tabarrini, O.; Basu, A.; Danielson, U.H.; Neyts, J.; Cecchetti, V. Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication. J. Med. Chem., 2013, 56(6), 2270-2282.
[http://dx.doi.org/10.1021/jm301643a] [PMID: 23409936]
[6]
Manfroni, G.; Manvar, D.; Barreca, M.L.; Kaushik-Basu, N.; Leyssen, P.; Paeshuyse, J.; Cannalire, R.; Iraci, N.; Basu, A.; Chudaev, M.; Zamperini, C.; Dreassi, E.; Sabatini, S.; Tabarrini, O.; Neyts, J.; Cecchetti, V. New pyrazolobenzothiazine derivatives as hepatitis C virus NS5B polymerase palm site I inhibitors. J. Med. Chem., 2014, 57(8), 3247-3262.
[http://dx.doi.org/10.1021/jm401688h] [PMID: 24654886]
[7]
Kim, S.H.; Ramu, R.; Kwon, S.W.; Lee, S.H.; Kim, C.H.; Kang, S.K.; Rhee, S.D.; Bae, M.A.; Ahn, S.H.; Ha, D.C.; Cheon, H.G.; Kim, K.Y.; Ahn, J.H. Discovery of cyclicsulfonamide derivatives as 11 β-hydroxysteroid dehydrogenase 1 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(3), 1065-1069.
[http://dx.doi.org/10.1016/j.bmcl.2009.12.035] [PMID: 20045318]
[8]
Kim, S.H.; Kwon, S.W.; Chu, S.Y.; Lee, J.H.; Narsaiah, B.; Kim, C.H.; Kang, S.K.; Kang, N.S.; Rhee, S.D.; Bae, M.A.; Ahn, S.H.; Ha, D.C.; Kim, K.Y.; Ahn, J.H. Identification of cyclicsulfonamide derivatives with an acetamide group as 11β-hydroxysteroid dehydrogenase 1 inhibitors. Chem. Pharm. Bull. (Tokyo), 2011, 59(1), 46-52.
[http://dx.doi.org/10.1248/cpb.59.46] [PMID: 21212546]
[9]
Lazer, E.S.; Miao, C.K.; Cywin, C.L.; Sorcek, R.; Wong, H.C.; Meng, Z.; Potocki, I.; Hoermann, M.; Snow, R.J.; Tschantz, M.A.; Kelly, T.A.; McNeil, D.W.; Coutts, S.J.; Churchill, L.; Graham, A.G.; David, E.; Grob, P.M.; Engel, W.; Meier, H.; Trummlitz, G. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J. Med. Chem., 1997, 40(6), 980-989.
[http://dx.doi.org/10.1021/jm9607010] [PMID: 9083488]
[10]
Wang, J.; Limburg, D.; Carter, J.; Mbalaviele, G.; Gierse, J.; Vazquez, M. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template. Bioorg. Med. Chem. Lett., 2010, 20(5), 1604-1609.
[http://dx.doi.org/10.1016/j.bmcl.2010.01.060] [PMID: 20144869]
[11]
Mamatha, N.; Babu, N.S.; Reddy, L.V.; Mukkanti, K.; Pal, S. Synthesis, characterization and anti-bacterial screening of Piroxicam based sulfonates. J. Chem. Pharm. Res., 2011, 3, 581-588.
[12]
Pal, S.; Bindu, P.; Dubey, P.K.; Chakraborty, S.; Mukherjee, A.K. Synthesis and structure analysis of cyclodehydration product of piroxicam: a metabolite detected in dogs and monkeys. Eur. J. Med. Chem., 2009, 44(8), 3368-3371.
[http://dx.doi.org/10.1016/j.ejmech.2009.03.010] [PMID: 19371981]
[13]
Naveen, K.; Rani, T.J.; Venkanna, B.; Babu, N.S.; Shree, A.J.; Pal, S. Novel benzoxepine-1,2,3-triazole hybrids: Synthesis and pharmacological evaluation as potential and anticancer agents. MedChemComm, 2015, 6, 1612-1619.
[http://dx.doi.org/10.1039/C5MD00224A]
[14]
Spellberg, B.; Gilbert, D.N. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clin. Infect. Dis., 2014, 59(Suppl. 2), S71-S75.
[http://dx.doi.org/10.1093/cid/ciu392] [PMID: 25151481]
[15]
Paul, M.; Gafter-Gvili, A.; Fraser, A.; Leibovici, L. The anti-cancer effects of quinolone antibiotics? Eur. J. Clin. Microbiol. Infect. Dis., 2007, 26(11), 825-831.
[http://dx.doi.org/10.1007/s10096-007-0375-4] [PMID: 17701431]
[16]
Wender, P.A.; Handy, S.T.; Wright, D.L. Towards the ideal synthesis. Chem. Ind., 1997, 19, 765-769.
[17]
Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click chemistry: Diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. Engl., 2001, 40(11), 2004-2021.
[http://dx.doi.org/10.1002/1521-3773(20010601)40:11<2004:AID-ANIE2004>3.0.CO;2-5] [PMID: 11433435]
[18]
Tornøe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem., 2002, 67(9), 3057-3064.
[http://dx.doi.org/10.1021/jo011148j] [PMID: 11975567]
[19]
Zia-ur-Rehman. M.; Choudary, J.A.; Ahmad, S. An Efficient Synthesis of 2-Alkyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. Bull. Korean Chem. Soc., 2005, 26, 1771-1775.
[http://dx.doi.org/10.5012/bkcs.2005.26.11.1771]
[20]
Crystal data for 4k: C20H17N5O7S (M =471.45 g/mol): orthorhombic, space group Pbca (no. 61), a = 14.308(2) Å, b = 13.3284(19) Å, c = 22.122(3) Å, V = 4218.7(11) Å3, Z = 8, T = 294.15 K, μ(MoKα) = 0.208 mm-1, Dcalc = 1.485 g/cm3, 46955 reflections measured (3.682° ≤ 2Θ ≤ 57.056°), 5251 unique (Rint = 0.0389, Rsigma = 0.0225) which were used in all calculations. The final R1 was 0.0662 (I > 2σ(I)) and wR2 was 0.1618 (all data). The Cambridge Crystallographic Data Centre supplementary publication number CCDC 850537 contains supplementary Crystallographic data for the structure. These data can be obtained free of charge at , www.ccdc.cam.ac.uk/conts/retrieving.html1618
[21]
Kavanagh, F. Analytical Microbiology; Academic Press: New York, London, 1972, Vol. II, pp. 11-23.
[22]
Miles, A.A.; Misra, S.S.; Irwin, J.O. The estimation of the bactericidal power of the blood. J. Hyg. (Lond.), 1938, 38(6), 732-749.
[PMID: 20475467]
[23]
NCI-60 Screening Methodology. NCI 60 cell one-dose screen., https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm
[24]
Alibek, K.; Bekmurzayeva, A.; Mussabekova, A.; Sultankulov, B. Using antimicrobial adjuvant therapy in cancer treatment: a review. Infect. Agent. Cancer, 2012, 7(1), 33.
[http://dx.doi.org/10.1186/1750-9378-7-33] [PMID: 23164412]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 10
Year: 2020
Published on: 27 May, 2020
Page: [929 - 940]
Pages: 12
DOI: 10.2174/1389557520666200124091315
Price: $65

Article Metrics

PDF: 21
HTML: 2